Advisors Management Group Inc. ADV Raises Stock Position in GSK plc (NYSE:GSK)

Advisors Management Group Inc. ADV raised its position in shares of GSK plc (NYSE:GSK) by 6.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 91,530 shares of the pharmaceutical company’s stock after buying an additional 5,259 shares during the period. Advisors Management Group Inc. ADV’s holdings in GSK were worth $3,096,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. FMR LLC grew its stake in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares during the period. Clifford Capital Partners LLC lifted its position in shares of GSK by 14.3% during the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after acquiring an additional 51,378 shares during the period. Cerity Partners LLC grew its holdings in GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after purchasing an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC increased its holdings in GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after acquiring an additional 83,433 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Price Performance

NYSE GSK opened at $32.88 on Thursday. The company has a 50 day simple moving average of $34.20 and a 200-day simple moving average of $38.08. The firm has a market capitalization of $68.15 billion, a price-to-earnings ratio of 21.35, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were paid a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.78%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. GSK’s payout ratio is presently 95.45%.

Analysts Set New Price Targets

A number of analysts recently commented on GSK shares. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.